Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Status:
Terminated
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab,
both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects
with recurrent or advanced non-squamous NSCLC